Neuron23 closes $96.5 million Series D financing round led by a healthcare investor to advance NEU-411 in Parkinson's disease.
Neuron23 closes $96.5 million Series D financing round led by a healthcare investor to advance NEU-411 in Parkinson's disease.
06/24/25, 2:00 PM
Location
san franciscoMoney raised
$96.5 million
Industry
biotechnology
Round Type
series d
Investors
Acorn Bioventures, Hbm Healthcare Investments (Cayman) Ltd., Kleiner Perkins, Blue Owl, Redmile Group, Soft Bank Vision Fund 2, Westlake Village Bio Partners
Neuron23 Inc. announced the closing of a $96.5 million Series D financing round, led by a healthcare investor. Existing investors include Westlake Village BioPartners, SoftBank Vision Fund 2, and others. This funding supports the NEULARK trial evaluating NEU-411 for early Parkinson’s disease
Company Info
Location
san francisco, california, united states
Additional Info
Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.